Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal ³²P or intravenous cyclophosphamide and cisplatin - a Gynecologic Oncology Group study

By Naumann R. Wendel  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 33-34

Informa Healthcare

Access to resources Recommend Favorite

Phase I Trial of Ifosfamide and 24-h Infusional Paclitaxel in Pelvic Malignancies: A Gynecologic Oncology Group Study

By Markman M.   Spriggs D.   Burger R.A.   Carson L.F.   Lentz S.S.   Gallion H.  

Gynecologic Oncology, Vol. 80, Iss. 3, 2001-03 ,pp. : 359-363

Elsevier

Access to resources Recommend Favorite

Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies

By Gold M.A.   Walker J.L.   Berek J.S.   Hallum A.V.   Garcia D.J.   Alberts D.S.  

Gynecologic Oncology, Vol. 90, Iss. 2, 2003-08 ,pp. : 325-330

Elsevier

Access to resources Recommend Favorite

Evaluation of low-dose intraperitoneal interferon- for palliation of ascites in patients with non-ovarian gynecologic malignancies

By Khabele D.   Runowicz C.D.   Fields A.L.   Anderson P.S.   Goldberg G.L.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 420-423

Elsevier

Access to resources Recommend Favorite

Laparoscopic Lymphadenectomy for Gynecologic Malignancies

By Dottino P.R.   Tobias D.H.   Beddoe A.   Golden A.L.   Cohen C.J.  

Gynecologic Oncology, Vol. 73, Iss. 3, 1999-06 ,pp. : 383-388

Elsevier

Access to resources Recommend Favorite